COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS A SECOND-LINE THERAPY FOR ADVANCED UROTHELIAL CARCINOMA IN THE UNITED STATES

被引：0
|
作者：
Chen, N. C. [1 ]
McQueen, R. [1 ]
机构：
[1] Univ Colorado, Anschutz Med Campus, Aurora, CO USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE369
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of pembrolizumab as second-line therapy for the treatment of locally advanced or metastatic urothelial carcinoma in the United States.
    Zhong, Yichen
    Lai, Yizhen
    Li, Haojie
    Batteson, Rachael
    Meng, Yang
    Frenkl, Tara L.
    Godwin, James Luke
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States
    Slater, Rachael Louise
    Lai, Yizhen
    Zhong, Yichen
    Li, Haojie
    Meng, Yang
    Moreno, Blanca Homet
    Godwin, James Luke
    Frenkl, Tara
    Sonpavde, Guru P.
    Mamtani, Ronac
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (09) : 967 - 977
  • [3] Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
    Srivastava, Tushar
    Prabhu, Vimalanand S.
    Li, Haojie
    Xu, Ruifeng
    Zarabi, Natalie
    Zhong, Yichen
    Pellissier, James M.
    Perini, Rodolfo F.
    de Wit, Ronald
    Mamtani, Ronac
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (05): : 663 - 670
  • [4] Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Wong, I.
    Choi, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S174 - S174
  • [5] Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
    Chiang, Chi-leung
    Chan, Sik-kwan
    Lee, Shing-fung
    Wong, Irene Oi-ling
    Choi, Horace Cheuk-wai
    JAMA NETWORK OPEN, 2021, 4 (01)
  • [6] Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States
    Hu, Jia
    Ye, Zhuomiao
    Xu, Zhe
    Hao, Zhinan
    Wang, Yongjun
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [7] Pembrolizumab as second-line therapy for advanced urothelial carcinoma
    Douchet, G.
    ONCOLOGIE, 2017, 19 (5-6) : 205 - 206
  • [8] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Bellmunt, J.
    de Wit, R.
    Vaughn, D. J.
    Fradet, Y.
    Lee, J. -L.
    Fong, L.
    Vogelzang, N. J.
    Climent, M. A.
    Petrylak, D. P.
    Choueiri, T. K.
    Necchi, A.
    Gerritsen, W.
    Gurney, H.
    Quinn, D. I.
    Culine, S.
    Sternberg, C. N.
    Mai, Y.
    Poehlein, C. H.
    Perini, R. F.
    Bajorin, D. F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11): : 1015 - 1026
  • [9] COST-EFFECTIVENESS OF PEMBROLIZUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED UROTHELIAL CANCER IN FRANCE
    Robert, J.
    Culine, S.
    Roupret, M.
    Zhong, Y.
    Prabhu, V. S.
    Xu, R.
    Li, H.
    Lafuma, A.
    Bensimon, L.
    Clement, A.
    VALUE IN HEALTH, 2018, 21 : S44 - S44
  • [10] Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Zhu, Guiqi
    Wu, Qiuji
    Wen, Feng
    Bai, Liangliang
    Li, Qiu
    LIVER INTERNATIONAL, 2019, 39 (12) : 2408 - 2416
12345